Volume | 8,412 |
|
|||||
News | - | ||||||
Day High | 0.274999 | Low High |
|||||
Day Low | 0.251 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.251 | 0.251 | 0.274999 | 0.261 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
62 | 8,412 | $ 0.2614894 | $ 2,200 | - | 0.2053 - 1.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:56:50 | 400 | $ 0.2699 | USD |
Sunshine Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.95M | 25.75M | - | 4.35M | -26.74M | -1.04 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sunshine Biopharma News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.28 | 0.2951 | 0.2314 | 0.2756079 | 119,073 | -0.0101 | -3.61% |
1 Month | 0.2741 | 0.3186 | 0.2053 | 0.260518 | 290,863 | -0.0042 | -1.53% |
3 Months | 0.37 | 0.4019 | 0.2053 | 0.2808975 | 146,266 | -0.1001 | -27.05% |
6 Months | 0.637 | 0.66 | 0.2053 | 0.424382 | 181,071 | -0.3671 | -57.63% |
1 Year | 0.718 | 1.40 | 0.2053 | 0.7870428 | 476,223 | -0.4481 | -62.41% |
3 Years | 2.75 | 9.87 | 0.2053 | 4.39 | 2,102,115 | -2.48 | -90.19% |
5 Years | 2.75 | 9.87 | 0.2053 | 4.39 | 2,102,115 | -2.48 | -90.19% |
Sunshine Biopharma Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |